Document is current
Any future updates will be listed below
-
Authors
da Silva Padilha, Miguel https://orcid.org/0000-0001-8141-7163
Koyuncu, Seda
Chabanis, Evangeline
Ryazanov, Sergey
Leonov, Andrei https://orcid.org/0000-0002-5586-9382
Vilchez, David https://orcid.org/0000-0002-0801-0743
Klein, Rüdiger https://orcid.org/0000-0002-3109-0163
Giese, Armin
Griesinger, Christian https://orcid.org/0000-0002-1266-4344
Dudanova, Irina https://orcid.org/0000-0003-1052-8485
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SPP2453 project number 541742535)
Deutsche Forschungsgemeinschaft (SFB1451 project number 431549029)
Deutsche Forschungsgemeinschaft (EXC 2030-390661388)
Deutsche Forschungsgemeinschaft (EXC 2030-390661388)
Deutsche Forschungsgemeinschaft (EXC 2067/1-390729940)
Deutsche Forschungsgemeinschaft (FOR5762 project number 531902955)
- License Information
-
More Information
Article History
Received: 5 March 2025
Revised: 18 May 2026
Accepted: 20 May 2026
First Online: 26 June 2026
Disclosure and competing interests statement
: AG and CG are co-founders and shareholders of MODAG. AG is a full-time employee of MODAG. AL and SR are partly employed by MODAG and are beneficiaries of the phantom share program of MODAG GmbH. AL, SR, CG, and AG are co-inventors of WO/2010/000372. Anle138b is licensed by Teva Pharmaceutical Industries Ltd and is in clinical development in collaboration with MODAG.
